Cancer Biotherapy and Radiopharmaceuticals

Papers
(The H4-Index of Cancer Biotherapy and Radiopharmaceuticals is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Long Non-Coding RNA AC008972.1 as a Novel Therapeutic Target for Prostate Cancer28
LncRNA MORT Overexpression Inhibits Cancer Cell Migration and Invasion in Hepatocellular Carcinoma by Downregulating NOTCH127
Expression of HER2 and BRCA1 Correlates with Prognosis in Patients with Breast Cancer After Radiotherapy: 26
miR-146a Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel by Downregulating IRAK124
Long Noncoding RNA Regulator of Reprogramming Regulates Cell Growth, Metastasis, and Cisplatin Resistance in Gastric Cancer via miR-519d-3p/HMGA2 Axis22
Knockdown of Circ_CCNB2 Sensitizes Prostate Cancer to Radiation Through Repressing Autophagy by the miR-30b-5p/KIF18A Axis22
Synergistic Effects of Ultrasound and Lenvatinib on Proliferation Inhibition and Apoptosis Induction in Hepatocellular Carcinoma Cells20
IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma20
An LNM-Associated Gene Signature for Prognostic Prediction and Immune Profiling in Head and Neck Squamous Cell Carcinoma19
Radiopharmaceutical Advancements in Anesthesia and Orthopedic Oncology: A Paradigm Shift in Cancer Biotherapy and Targeted Therapy19
Telomere-Related Gene Risk Model for Prognosis and Immune Landscape in Hepatocellular Carcinoma19
Long Noncoding RNA MALAT1 Knockdown Inhibits Proliferation, Migration, and Invasion and Promotes Apoptosis in Non-Small-Cell Lung Cancer Cells Through Re18
MICA/MICB-Mediated NKG2D Immune Escape in Cervical Cancer: Single-Cell Transcriptomic Mapping of Radionuclide Therapy Targets for Precision Radioimmunotherapy16
Radionuclide-Based Theranostic Mapping for Spatially Optimized Treatment Planning in Cervical Carcinoma15
0.15420198440552